FDAnews Drug Daily Bulletin

Impax Can Launch Generic Renvela, Renagel in 2014 Following Genzyme Settlement

Sept. 6, 2012
Impax Laboratories can market generic versions of Genzyme’s kidney disease drugs Renvela and Renagel in 2014 under a settlement with the brand drugmaker. Genzyme has granted Impax a license to sell a generic version of Renvela (sevelamer carbonate) 800-mg tablets beginning March 16, 2014, Impax said Tuesday. Impax can also sell oral suspension versions of Renvela and Renagel (sevelamer hydrochloride) beginning Sept. 16, 2014.
Drug Industry Daily